Intravitreal Drug Therapy for Retinal Vein Occlusion - Pathophysiological Mechanisms and Routinely Used Drugs
2010 | review. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Intravitreal Drug Therapy for Retinal Vein Occlusion - Pathophysiological Mechanisms and Routinely Used Drugs
Feltgen, N.; Pielen, A.; Hansen, L.; Bertram, B.; Agostini, H. T.; Jaissle, G. B.& Hoerauf, H. et al. (2010)
Klinische Monatsblätter für Augenheilkunde, 227(9) pp. 681-693.
Georg Thieme Verlag Kg. DOI: https://doi.org/10.1055/s-0029-1245606
Documents & Media
Details
- Authors
- Feltgen, Nicolas; Pielen, A.; Hansen, L.; Bertram, B.; Agostini, Hansjuergen T.; Jaissle, Gesine B.; Hoerauf, Hans; Stahl, Andreas
- Abstract
- The novel therapeutic principle of intravitreal drug therapy for retinal vein occlusion has become an integrated constituent of clinical practice over the last years. The two substance classes that have been evaluated in large randomised clinical trials so far are corticosteroids and inhibitors of vascular endothelial growth factor (VEGF). The reported treatment success of these intravitreally administered substances has lead not only to a paradigm shift in clinical care but has also advanced our understanding of the underlying pathophysiological principles of retinal vein occlusions. In this review the different substances are discussed, their mechanisms of action are analysed and the results of the large clinical trials available to date are critically evaluated. Furthermore, an approach to integrate these novel treatment options into the exisitng treatment regimes for retinal vein occlusions is suggested.
- Issue Date
- 2010
- Status
- published
- Publisher
- Georg Thieme Verlag Kg
- Journal
- Klinische Monatsblätter für Augenheilkunde
- ISSN
- 1439-3999; 0023-2165